Advertisement

Functional Mitral Valve Regurgitation

  • Paul A. GrayburnEmail author
Secondary Prevention and Intervention (D. Steinberg, Section Editor)
  • 6 Downloads
Part of the following topical collections:
  1. Topical Collection on Secondary Prevention and Intervention

Abstract

Purpose of Review

Functional mitral regurgitation (FMR) occurs when mitral leaflets are prevented from adequate coaptation by underlying left ventricular (LV) dysfunction, mitral annular dilation, or both. This review aims to clarify the complex clinical issues in FMR, including diagnosis and therapy.

Recent Findings

Even mild FMR has been shown to affect survival negatively. FMR is a dynamic condition and can vary within systole and with altered loading conditions. An integrative approach, including qualitative and quantitative echocardiographic data, is mandatory to determine severity of FMR. Treatment of FMR starts with guideline-directed medical therapy (GDMT) for LV dysfunction and heart failure, including cardiac resynchronization and/or revascularization, when indicated. Although mitral valve surgery may be considered in patients undergoing CABG in whom moderate or greater FMR is present, there is no convincing evidence that surgery improves outcomes. Recently, two randomized trials have compared percutaneous edge-to-edge repair of the mitral valve to GDMT. One showed striking benefit in patients with severe FMR and smaller LV volumes; the other no benefit in moderate MR with larger LV volumes.

Summary

FMR is a complex condition in which underlying LV dysfunction interrupts proper closure of the mitral leaflets. FMR can improve with GDMT for heart failure due to LV dysfunction. When it persists despite optimal titration of GDMT, transcatheter edge-to-edge mitral valve repair can improve mortality, heart failure hospitalization, and quality of life in selected patients. Trials of transcatheter mitral valve replacement are underway.

Keywords

Mitral regurgitation Heart failure Left ventricular dysfunction MitraClip Valvular heart disease 

Notes

Compliance with Ethical Standards

Conflict of Interest

Dr. Grayburn receives research grant support from Abbott Vascular, Boston Scientific, Edwards Lifesciences, and Medtronic, Echo Core Lab contracts from Edwards Lifesciences, W. L. Gore, Neochord, and Cardiovalve. He is a consultant for Abbott Vascular, Edwards Lifesciences, and Neochord.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005–11.CrossRefGoogle Scholar
  2. 2.
    de Marchena E, Badiye A, Robalino G, Junttila J, Atapattu S, Nakamura M, et al. Respective prevalence of the different Carpentier classes of mitral regurgitation: a stepping stone for future therapeutic research and development. Journal of cardiac surgery. 2011;26:385–92.CrossRefGoogle Scholar
  3. 3.
    Grigioni F, Enriquez-Sarano M, Zehr KJ, Bailey KR, Tajik AJ. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation. 2001;103:1759–64.CrossRefGoogle Scholar
  4. 4.
    Ellis SG, Whitlow PL, Raymond RE, Schneider JP. Impact of mitral regurgitation on long-term survival after percutaneous coronary intervention. The American journal of cardiology. 2002;89:315–8.CrossRefGoogle Scholar
  5. 5.
    Pellizzon GG, Grines CL, Cox DA, Stuckey T, Tcheng JE, Garcia E, et al. Importance of mitral regurgitation inpatients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Journal of the American College of Cardiology. 2004;43:1368–74.CrossRefGoogle Scholar
  6. 6.
    Lamas GA, Mitchell GF, Flaker GC, Smith SC Jr, Gersh BJ, Basta L, et al. Clinical significance of mitral regurgitation after acute myocardial infarction. Survival and ventricular enlargement investigators. Circulation. 1997;96:827–33.CrossRefGoogle Scholar
  7. 7.
    Trichon BH, Felker GM, Shaw LK, Cabell CH, O’Connor CM. Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. The American journal of cardiology. 2003;91:538–43.CrossRefGoogle Scholar
  8. 8.
    Deja MA, Grayburn PA, Sun B, Rao V, She L, Krejca M, et al. Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. Circulation. 2012;125:2639–48.CrossRefGoogle Scholar
  9. 9.
    Grayburn PA, Appleton CP, DeMaria AN, Greenberg B, Lowes B, Oh J, et al. Investigators BEST. Echocardiographic predictors of morbidity and mortality in patients with advanced heart failure: the beta-blocker evaluation of survival trial (BEST). Journal of the American College of Cardiology. 2005;45:1064–71.CrossRefGoogle Scholar
  10. 10.
    Cioffi G, Tarantini L, De Feo S, Pulignano G, Del Sindaco D, Stefenelli C, et al. Functional mitral regurgitation predicts 1-year mortality in elderly patients with systolic chronic heart failure. European journal of heart failure. 2005;7:1112–7.CrossRefGoogle Scholar
  11. 11.
    Rossi A, Dini FL, Faggiano P, Agricola E, Cicoira M, Frattini S, et al. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. Heart. 2011;97:1675–80.CrossRefGoogle Scholar
  12. 12.
    Levine RA, Schwammenthal E. Ischemic mitral regurgitation on the threshold of a solution: from paradoxes to unifying concepts. Circulation. 2005;112:745–58.CrossRefGoogle Scholar
  13. 13.
    Nishino S, Watanabe N, Kimura T, Enriquez-Sarano M, Nakama T, Furugen M, et al. The course of ischemic mitral regurgitation in acute myocardial infarction after primary percutaneous coronary intervention: from emergency room to long-term follow-up. Circulation. Cardiovascular imaging. 2016;9:e004841.CrossRefGoogle Scholar
  14. 14.
    Sannino A, Grayburn PA. Ischemic mitral regurgitation after acute myocardial infarction in the percutaneous coronary intervention era. Circulation. Cardiovascular imaging. 2016;9:e005323.CrossRefGoogle Scholar
  15. 15.
    Nakai H, Kaku K, Takeuchi M, Otani K, Yoshitani H, Haruki N, et al. Different influences of left ventricular remodeling on anterior and posterior mitral leaflet tethering. Circulation journal: official journal of the Japanese Circulation Society. 2012;76:2481–7.CrossRefGoogle Scholar
  16. 16.
    Hashim SW, Youssef SJ, Ayyash B, Rousou AJ, Ragnarsson S, Collazo S, et al. Pseudoprolapse of the anterior leaflet in chronic ischemic mitral regurgitation: identification and repair. The Journal of thoracic and cardiovascular surgery. 2012;143:S33–7.CrossRefGoogle Scholar
  17. 17.
    Kaul S, Spotnitz WD, Glasheen WP, Touchstone DA. Mechanism of ischemic mitral regurgitation. An experimental evaluation. Circulation. 1991;84:2167–80.CrossRefGoogle Scholar
  18. 18.
    Meris A, Amigoni M, Verma A, Thune JJ, Kober L, Velazquez E, et al. Valsartan in acute myocardial infarction I. Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction. Journal of the American Society of Echocardiography: official publication of the American Society of Echocardiography. 2012;25:535–42.CrossRefGoogle Scholar
  19. 19.
    Beaudoin J, Handschumacher MD, Zeng X, Hung J, Morris EL, Levine RA, et al. Mitral valve enlargement in chronic aortic regurgitation as a compensatory mechanism to prevent functional mitral regurgitation in the dilated left ventricle. Journal of the American College of Cardiology. 2013;61:1809–16.CrossRefGoogle Scholar
  20. 20.
    Chaput M, Handschumacher MD, Tournoux F, Hua L, Guerrero JL, Vlahakes GJ, et al. Mitral leaflet adaptation to ventricular remodeling: occurrence and adequacy in patients with functional mitral regurgitation. Circulation. 2008;118:845–52.CrossRefGoogle Scholar
  21. 21.
    Grayburn PA. New concepts in functional mitral regurgitation: it is not just a disease of the left ventricle. Journal of the American College of Cardiology. 2013;61:1817–9.CrossRefGoogle Scholar
  22. 22.
    Kwan J, Shiota T, Agler DA, Popovic ZB, Qin JX, Gillinov MA, et al. Real-time three-dimensional echocardiography s. Geometric differences of the mitral apparatus between ischemic and dilated cardiomyopathy with significant mitral regurgitation: real-time three-dimensional echocardiography study. Circulation. 2003;107:1135–40.CrossRefGoogle Scholar
  23. 23.
    Gertz ZM, Raina A, Saghy L, Zado ES, Callans DJ, Marchlinski FE, et al. Evidence of atrial functional mitral regurgitation due to atrial fibrillation: reversal with arrhythmia control. Journal of the American College of Cardiology. 2011;58:1474–81.CrossRefGoogle Scholar
  24. 24.
    Carpentier A. Cardiac valve surgery—the “French correction”. The Journal of thoracic and cardiovascular surgery. 1983;86:323–37.PubMedGoogle Scholar
  25. 25.
    Zoghbi WA, Adams D, Bonow RO, Enrquez-Sarano M, Foster E, Grayburn PA, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2017;30:303–71.CrossRefGoogle Scholar
  26. 26.
    Lancellotti P, Moura L, Pierard LA, Agricola E, Popescu BA, Tribouilloy C, et al. European Association of E. European association of echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease). European journal of echocardiography: the journal of the Working Group on Echocardiography of the European Society of Cardiology. 2010;11:307–32.CrossRefGoogle Scholar
  27. 27.
    Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. American College of Cardiology/American Heart Association Task Force on Practice G. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2014;63:e57–185.CrossRefGoogle Scholar
  28. 28.
    Joint Task Force on the Management of Valvular Heart Disease of the European Society of C, European Association for Cardio-Thoracic S, Vahanian A, Alfieri O, Andreotti F, Antunes MJ, et al. Guidelines on the management of valvular heart disease (version 2012). European heart journal. 2012;33:2451–96.CrossRefGoogle Scholar
  29. 29.
    Grayburn PA, Weissman NJ, Zamorano JL. Quantitation of mitral regurgitation. Circulation. 2012;126:2005–17.CrossRefGoogle Scholar
  30. 30.
    Mittal AK, Langston M Jr, Cohn KE, Selzer A, Kerth WJ. Combined papillary muscle and left ventricular wall dysfunction as a cause of mitral regurgitation. An experimental study. Circulation. 1971;44:174–80.CrossRefGoogle Scholar
  31. 31.
    Lancellotti P, Lebrun F, Pierard LA. Determinants of exercise-induced changes in mitral regurgitation in patients with coronary artery disease and left ventricular dysfunction. Journal of the American College of Cardiology. 2003;42:1921–8.CrossRefGoogle Scholar
  32. 32.
    Shiran A, Merdler A, Ismir E, Ammar R, Zlotnick AY, Aravot D, et al. Intraoperative transesophageal echocardiography using a quantitative dynamic loading test for the evaluation of ischemic mitral regurgitation. Journal of the American Society of Echocardiography: official publication of the American Society of Echocardiography. 2007;20:690–7.CrossRefGoogle Scholar
  33. 33.
    Pierard LA, Lancellotti P. The role of ischemic mitral regurgitation in the pathogenesis of acute pulmonary edema. The New England journal of medicine. 2004;351:1627–34.CrossRefGoogle Scholar
  34. 34.
    Lancellotti P, Troisfontaines P, Toussaint AC, Pierard LA. Prognostic importance of exercise-induced changes in mitral regurgitation in patients with chronic ischemic left ventricular dysfunction. Circulation. 2003;108:1713–7.CrossRefGoogle Scholar
  35. 35.
    Pierard LA, Lancellotti P. Stress testing in valve disease. Heart. 2007;93:766–72.CrossRefGoogle Scholar
  36. 36.
    Hundley WG, Li HF, Willard JE, Landau C, Lange RA, Meshack BM, et al. Magnetic resonance imaging assessment of the severity of mitral regurgitation. Comparison with invasive techniques. Circulation. 1995;92:1151–8.CrossRefGoogle Scholar
  37. 37.
    Gelfand EV, Hughes S, Hauser TH, Yeon SB, Goepfert L, Kissinger KV, et al. Severity of mitral and aortic regurgitation as assessed by cardiovascular magnetic resonance: optimizing correlation with Doppler echocardiography. Journal of cardiovascular magnetic resonance: official journal of the Society for Cardiovascular Magnetic Resonance. 2006;8:503–7.CrossRefGoogle Scholar
  38. 38.
    Schiros CG, Dell’Italia LJ, Gladden JD, Clark D 3rd, Aban I, Gupta H, et al. Magnetic resonance imaging with 3-dimensional analysis of left ventricular remodeling in isolated mitral regurgitation: implications beyond dimensions. Circulation. 2012;125:2334–42.CrossRefGoogle Scholar
  39. 39.
    Writing Committee M, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134:e282–93.Google Scholar
  40. 40.
    Comin-Colet J, Sanchez-Corral MA, Manito N, Gomez-Hospital JA, Roca J, Fernandez-Nofrerias E, et al. Effect of carvedilol therapy on functional mitral regurgitation, ventricular remodeling, and contractility in patients with heart failure due to left ventricular systolic dysfunction. Transplantation proceedings. 2002;34:177–8.CrossRefGoogle Scholar
  41. 41.
    Harshaw CW, Grossman W, Munro AB, McLaurin LP. Reduced systemic vascular resistance as therapy for severe mitral regurgitation of valvular origin. Annals of internal medicine. 1975;83:312–6.CrossRefGoogle Scholar
  42. 42.
    Boriani G, Gasparini M, Landolina M, Lunati M, Biffi M, Santini M, et al. InSync/InSync ICDIRI. Impact of mitral regurgitation on the outcome of patients treated with CRT-D: data from the InSync ICD Italian Registry. Pacing and clinical electrophysiology: PACE. 2012;35:146–54.CrossRefGoogle Scholar
  43. 43.
    Onishi T, Onishi T, Marek JJ, Ahmed M, Haberman SC, Oyenuga O, et al. Mechanistic features associated with improvement in mitral regurgitation after cardiac resynchronization therapy and their relation to long-term patient outcome. Circulation. Heart failure. 2013;6:685–93.CrossRefGoogle Scholar
  44. 44.
    Xu YZ, Cha YM, Feng D, Powell BD, Wiste HJ, Hua W, et al. Impact of myocardial scarring on outcomes of cardiac resynchronization therapy: extent or location? Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2012;53:47–54.CrossRefGoogle Scholar
  45. 45.
    Di Biase L, Auricchio A, Mohanty P, Bai R, Kautzner J, Pieragnoli P, et al. Impact of cardiac resynchronization therapy on the severity of mitral regurgitation. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2011;13:829–38.CrossRefGoogle Scholar
  46. 46.
    Leor J, Feinberg MS, Vered Z, Hod H, Kaplinsky E, Goldbourt U, et al. Effect of thrombolytic therapy on the evolution of significant mitral regurgitation in patients with a first inferior myocardial infarction. Journal of the American College of Cardiology. 1993;21:1661–6.CrossRefGoogle Scholar
  47. 47.
    Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. Shock investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. The New England journal of medicine. 1999;341:625–34.CrossRefGoogle Scholar
  48. 48.
    Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. The New England journal of medicine. 2011;364:1607–16.CrossRefGoogle Scholar
  49. 49.
    Kang DH, Sun BJ, Kim DH, Yun SC, Song JM, Choo SJ, et al. Percutaneous versus surgical revascularization in patients with ischemic mitral regurgitation. Circulation. 2011;124:S156–62.CrossRefGoogle Scholar
  50. 50.
    McGee EC, Gillinov AM, Blackstone EH, Rajeswaran J, Cohen G, Najam F, et al. Recurrent mitral regurgitation after annuloplasty for functional ischemic mitral regurgitation. The Journal of thoracic and cardiovascular surgery. 2004;128:916–24.CrossRefGoogle Scholar
  51. 51.
    Wong DR, Agnihotri AK, Hung JW, Vlahakes GJ, Akins CW, Hilgenberg AD, et al. Long-term survival after surgical revascularization for moderate ischemic mitral regurgitation. The Annals of thoracic surgery. 2005;80:570–7.CrossRefGoogle Scholar
  52. 52.
    Kang DH, Kim MJ, Kang SJ, Song JM, Song H, Hong MK, et al. Mitral valve repair versus revascularization alone in the treatment of ischemic mitral regurgitation. Circulation. 2006;114:I499–503.PubMedGoogle Scholar
  53. 53.
    Lee AP, Acker M, Kubo SH, Bolling SF, Park SW, Bruce CJ, et al. Mechanisms of recurrent functional mitral regurgitation after mitral valve repair in nonischemic dilated cardiomyopathy: Importance of distal anterior leaflet tethering. Circulation. 2009;119:2606–14.CrossRefGoogle Scholar
  54. 54.
    Gelsomino S, van Garsse L, Luca F, Lorusso R, Cheriex E, Rao CM, et al. Impact of preoperative anterior leaflet tethering on the recurrence of ischemic mitral regurgitation and the lack of left ventricular reverse remodeling after restrictive annuloplasty. Journal of the American Society of Echocardiography: official publication of the American Society of Echocardiography. 2011;24:1365–75.CrossRefGoogle Scholar
  55. 55.
    Roshanali F, Mandegar MH, Yousefnia MA, Rayatzadeh H, Alaeddini F. A prospective study of predicting factors in ischemic mitral regurgitation recurrence after ring annuloplasty. The Annals of thoracic surgery. 2007;84:745–9.CrossRefGoogle Scholar
  56. 56.
    Mihaljevic T, Lam BK, Rajeswaran J, Takagaki M, Lauer MS, Gillinov AM, et al. Impact of mitral valve annuloplasty combined with revascularization in patients with functional ischemic mitral regurgitation. Journal of the American College of Cardiology. 2007;49:2191–201.CrossRefGoogle Scholar
  57. 57.
    Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling TM. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. Journal of the American College of Cardiology. 2005;45:381–7.CrossRefGoogle Scholar
  58. 58.
    Michler RE, Smith PK, Parides MK, Ailawadi G, Thourani V, Moskowitz AJ, et al. Ctsn. Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation. The New England journal of medicine. 2016;374:1932–41.CrossRefGoogle Scholar
  59. 59.
    Acker MA, Bolling S, Shemin R, Kirklin J, Oh JK, Mann DL, et al. Acorn Trial Principal I, Study C. Mitral valve surgery in heart failure: insights from the Acorn Clinical Trial. The Journal of thoracic and cardiovascular surgery. 2006;132:568–77 e561–564.CrossRefGoogle Scholar
  60. 60.
    Braun J, Bax JJ, Versteegh MI, Voigt PG, Holman ER, Klautz RJ, et al. Preoperative left ventricular dimensions predict reverse remodeling following restrictive mitral annuloplasty in ischemic mitral regurgitation. European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery. 2005;27:847–53.CrossRefGoogle Scholar
  61. 61.
    Bolling SF, Deeb GM, Brunsting LA, Bach DS. Early outcome of mitral valve reconstruction in patients with end-stage cardiomyopathy. The Journal of thoracic and cardiovascular surgery. 1995;109:676–82 discussion 682–673.CrossRefGoogle Scholar
  62. 62.
    Bach DS, Bolling SF. Improvement following correction of secondary mitral regurgitation in end-stage cardiomyopathy with mitral annuloplasty. The American journal of cardiology. 1996;78:966–9.CrossRefGoogle Scholar
  63. 63.
    Goldstein D, Moskowitz AJ, Gelijns AC, Ailawadi G, Parides MK, Perrault LP, et al. Ctsn. Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation. The New England journal of medicine. 2016;374:344–53.CrossRefGoogle Scholar
  64. 64.
    Hung J, Papakostas L, Tahta SA, Hardy BG, Bollen BA, Duran CM, et al. Mechanism of recurrent ischemic mitral regurgitation after annuloplasty: continued LV remodeling as a moving target. Circulation. 2004;110:II85–90.CrossRefGoogle Scholar
  65. 65.
    Digiammarco G, Liberi R, Giancane M, Canosa C, Gallina S, Di Francesco A, et al. Recurrence of functional mitral regurgitation in patients with dilated cardiomyopathy undergoing mitral valve repair: how to predict it. Interactive cardiovascular and thoracic surgery. 2007;6:340–4.CrossRefGoogle Scholar
  66. 66.
    Magne J, Pibarot P, Dagenais F, Hachicha Z, Dumesnil JG, Senechal M. Preoperative posterior leaflet angle accurately predicts outcome after restrictive mitral valve annuloplasty for ischemic mitral regurgitation. Circulation. 2007;115:782–91.CrossRefGoogle Scholar
  67. 67.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2013;62:e147–239.CrossRefGoogle Scholar
  68. 68.
    Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, et al. Percutaneous repair or surgery for mitral regurgitation. The New England journal of medicine. 2011;364:1395–406.CrossRefGoogle Scholar
  69. 69.
    Mauri L, Foster E, Glower DD, Apruzzese P, Massaro JM, Herrmann HC, et al. 4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation. Journal of the American College of Cardiology. 2013;62:317–28.CrossRefGoogle Scholar
  70. 70.
    Foster E, Kwan D, Feldman T, Weissman NJ, Grayburn PA, Schwartz A, et al. Percutaneous mitral valve repair in the initial EVEREST cohort: evidence of reverse left ventricular remodeling. Circulation. Cardiovascular imaging. 2013;6:522–30.CrossRefGoogle Scholar
  71. 71.
    Grayburn PA, Foster E, Sangli C, Weissman NJ, Massaro J, Glower DG, et al. Relationship between the magnitude of reduction in mitral regurgitation severity and left ventricular and left atrial reverse remodeling after MitraClip therapy. Circulation. 2013;128:1667–74.CrossRefGoogle Scholar
  72. 72.
    Auricchio A, Schillinger W, Meyer S, Maisano F, Hoffmann R, Ussia GP, et al. Correction of mitral regurgitation in nonresponders to cardiac resynchronization therapy by MitraClip improves symptoms and promotes reverse remodeling. Journal of the American College of Cardiology. 2011;58:2183–9.CrossRefGoogle Scholar
  73. 73.
    • Stone GW, Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379:2307–18 First randomized clinical trial to demonstrate a benefit for transcatheter mitral valve repair on heart failure hospitalization and mortality. CrossRefGoogle Scholar
  74. 74.
    • Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med. 2018;379:2297–306 Randomized clinical trial of transcatheter mitral valve repair with patients with values for MR severity known to be associated with mortality. It showed no benefit on the combined endpoint of mortality and heart failure hospitalization. CrossRefGoogle Scholar
  75. 75.
    •• Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials. JACC: Cardiovasc Imaging. 2019;12:353–62 Using the Gorlin hydraulic orifice area equation, the authors show a hemodynamic conceptual framework that explains the different results of the two randomized trials of transcatheter mitral valve repair in secondary MR. Google Scholar
  76. 76.
    Siminiak T, Wu JC, Haude M, Hoppe UC, Sadowski J, Lipiecki J, et al. Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the titan trial. European journal of heart failure. 2012;14:931–8.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Internal Medicine, Cardiology DivisionBaylor University Medical CenterDallasUSA
  2. 2.Baylor Scott and White Heart and Vascular Hospital DallasDallasUSA

Personalised recommendations